The EPO published patent EP3806902A1 covering compositions and methods for preventing or reversing T-cell exhaustion via ectonucleotidase inhibition, specifically targeting CD39/CD73 pathways. The application includes claims for anti-CD39 antibodies (C07K 16/28), therapeutic formulations (A61K 39/00), and combination therapies for cancer treatment. Inventors include Simon C. Robson, Yan Shang, Wenda Gao, Haohai Zhang, and Paola de Andrade Mello. Designated states cover all EU member states plus associated countries.

This is a patent publication rather than a regulatory requirement. Compliance teams in pharmaceutical and biotech companies should review for freedom-to-operate considerations if developing immunooncology programs targeting T-cell exhaustion pathways. No immediate compliance deadlines or penalties apply to this IP publication.